Phosphatidylserine, Bacopa, and Lion's Mane: A Reference Guide to Evidence-Based Compounds

Why these three compounds

Phosphatidylserine, Bacopa monnieri, and lion's mane mushroom (Hericium erinaceus) appear repeatedly in the nootropic literature for a specific reason: each has been evaluated in multiple controlled human trials, not just animal or cell models. That does not make them interchangeable or universally effective, but it does mean the clinical picture is more developed than for many other compounds in this space.

This reference profiles each compound separately, covering its proposed mechanism, what the clinical evidence shows, the dosage ranges studied (not prescribed), and where the evidence has limits. For broader context on how nootropics are categorized, see how the main nootropic categories differ. Always consult a qualified healthcare professional before adding any compound to your health routine.

Phosphatidylserine

Phosphatidylserine (PS) is a phospholipid that occurs naturally in cell membranes, with the highest concentrations in brain tissue. It supports membrane fluidity and is involved in signal transduction between neurons. Endogenous PS declines with age, which has made it a target for research into age-related cognitive changes.

What trials have examined: Multiple randomized, double-blind trials, particularly in older adults with mild memory complaints, have found PS supplementation associated with modest improvements in verbal recall and attention compared with placebo. A body of research published across the 1990s and early 2000s formed the basis for a qualified health claim recognized by the U.S. Food and Drug Administration (FDA), though the FDA notes that the evidence is limited and inconclusive.

Dosage context in research: Most trials used 300 mg per day divided across three doses, over 12 weeks or longer. Results in cognitively healthy younger adults are less consistent.

Limitations: Earlier studies used bovine-sourced PS; most current supplements use soy- or sunflower-derived PS, which has a slightly different fatty acid profile. Whether the two are equivalent in effect is not fully established. Interactions with blood-thinning medications have been noted in clinical literature, so people on anticoagulant therapy should discuss PS with a physician before use.

Bacopa monnieri

Bacopa monnieri is an aquatic herb used in Ayurvedic medicine for centuries. Its active constituents, called bacosides, are thought to modulate synaptic transmission, reduce oxidative stress in neurons, and support acetylcholine activity, the neurotransmitter most associated with memory consolidation.

What trials have examined: Several randomized controlled trials in healthy adults have found Bacopa associated with improvements in delayed word recall and processing speed relative to placebo. A 2001 trial published in Psychopharmacology by Roodenrys and colleagues found significant effects on verbal learning rate after 12 weeks. A 2008 trial by Morgan and Stevens in The Journal of Alternative and Complementary Medicine reported similar findings in adults over 55. Effect sizes are generally moderate.

Dosage context in research: Trials most commonly used standardized extracts providing 300 to 450 mg per day. Bacopa is considered an adaptogen, and the literature suggests benefits accumulate over weeks rather than producing acute effects.

Limitations: Gastrointestinal side effects (nausea, cramping) are the most commonly reported adverse events. Bacopa may slow the processing of certain drugs metabolized by the liver. For context on how adaptogens compare with other nootropic families, see the adaptogen versus cholinergic comparison.

Lion's mane mushroom

Lion's mane contains bioactive compounds called hericenones (found in the fruiting body) and erinacines (found in the mycelium). These are among the few naturally occurring compounds shown in laboratory models to stimulate nerve growth factor (NGF) synthesis. NGF supports the survival and differentiation of neurons, making lion's mane a focus of neuroplasticity research.

What trials have examined: A frequently cited randomized controlled trial by Mori and colleagues (2009, Phytotherapy Research) found that adults aged 50 to 80 with mild cognitive impairment who took lion's mane extract for 16 weeks scored significantly higher on a cognitive function scale than the placebo group, with scores declining after cessation. Subsequent smaller trials have explored effects on mood and processing speed with mixed results.

Dosage context in research: The Mori trial used 3 grams per day of dried powder. Other studies have used standardized extracts at lower amounts. Fruiting-body versus mycelium sourcing affects the bioactive compound profile, and many commercial products do not specify which part is used.

Limitations: The evidence base is smaller than for PS or Bacopa, and most trials have been conducted in Asian populations, limiting generalizability. Rare allergic reactions have been reported. The NGF stimulation mechanism is well-supported in vitro, but direct demonstration in living human brain tissue remains an area of ongoing investigation. For a broader introduction to how evidence quality varies across nootropics, see a grounded introduction to nootropics.

This article provides general health information and is not medical advice. Consult a qualified healthcare professional before starting, stopping, or changing any supplement regimen, particularly if you have an existing medical condition, are pregnant, or take prescription medications.